Progyny (PGNY) Tops Q1 EPS by 26c, Revenue Misses, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Progyny, Inc. Announces First Quarter 2024 Results
May 9, 2024 4:01 PM EDTEarly Sales Activity and New Partnerships Provide Strong Start to Selling Season, Affirming Continued Demand for Fertility and Family Building Solutions
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (Progyny or the Company), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended March 31, 2024 (the first quarter of 2024) as compared to the three-month period ended March 31, 2023 (the first quarter of 2023 or the prior year period).
Utilization through the end of February was consistent with the record... More
